INBX
Inhibrx Biosciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputs8Q avg ±5.5%·×1.90·rich
straddle ±15.2%
spot 86.76exp Nov 20ATM strike 85ATM straddle 15.50IV 107%
−8.91%
vs ±11.9% implied · ×0.75
shaded = implied · ▲▼ = realized
Inhibrx Biosciences, Inc.
85.04
+3.96 · +4.88%
post 85.04 +0.01%
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Morgan StanleyMorgan Stanley | $123.9M | 9.45% | +3.56% | |
| 2 | Perceptive AdvisorsPerceptive | $123.0M | 9.38% | −10.05% | |
| 3 | SanofiSanofi | $109.7M | 8.37% | 0.00% | |
| 4 | Viking Global InvestorsViking Global Investors | $106.5M | 8.12% | −21.82% | |
| 5 | Bank of AmericaBank of America | $79.7M | 6.08% | +2473.63% | |
| 6 | BlackRockBlackRockindex-like | $78.3M | 5.97% | +3.39% | |
| 7 | Schonfeld Strategic AdvisorsSchonfeld Strategic | $66.1M | 5.04% | +173.75% | |
| 8 | State StreetState Streetindex-like | $60.7M | 4.63% | +16.27% | |
| 9 | Vanguard Capital ManagementVanguardindex-like | $46.7M | 3.56% | +1.24% | |
| 10 | Goldman Sachs GroupGoldman Sachs | $38.3M | 2.92% | +150.46% | |
| 11 | Woodline PartnersWoodline Partners | $38.0M | 2.90% | +4.28% | |
| 12 | Capital Research Global InvestorsCapital Research Global Investors | $34.4M | 2.62% | −7.58% | |
| 13 | Partner Fund ManagementPartner Fund | $29.2M | 2.23% | +0.97% | |
| 14 | Sofinnova InvestmentsSofinnova | $28.7M | 2.19% | −25.35% | |
| 15 | Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund | $25.7M | 1.96% | +59.17% | |
| 16 | Parkman Healthcare PartnersParkman Healthcare Partners | $24.3M | 1.86% | new | |
| 17 | Geode Capital ManagementGeodeindex-like | $24.3M | 1.85% | +10.65% | |
| 18 | CDC FinancialCDC Financial | $16.1M | 1.23% | −8.79% | |
| 19 | First Turn ManagementFirst Turn | $15.6M | 1.19% | new | |
| 20 | Millennium ManagementMillennium | $13.9M | 1.06% | −55.10% | |
| 21 | First Trust AdvisorsFirst Trust | $12.2M | 0.93% | new | |
| 22 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $11.6M | 0.89% | +69.14% | |
| 23 | Capitolis Liquid Global MarketsCapitolis Liquid Global Markets | $11.3M | 0.86% | −4.64% | |
| 24 | Susquehanna International GroupSusquehanna International | $9.7M | 0.74% | −34.95% | |
| 25 | Northern TrustNorthern Trustindex-like | $9.6M | 0.73% | +7.75% |
164 managers report $1.3B of Inhibrx Biosciences on form 13F for the quarter ended Jun 30 '26. 18 of them hold 80% of it; Morgan Stanley is largest at 9.45%.
Linked news